Novel Triazole Derivatives Containing Different Ester Skeleton: Design, Synthesis, Biological Evaluation and Molecular Docking
- PMID: 31708557
- DOI: 10.1248/cpb.c19-00624
Novel Triazole Derivatives Containing Different Ester Skeleton: Design, Synthesis, Biological Evaluation and Molecular Docking
Abstract
Invasive fungal disease constitutes a growing health problem and development of novel antifungal drugs with high potency and selectivity are in an urgent need. In this study, a novel series of triazole derivatives containing different ester skeleton were designed and synthesized. Microdilution broth method was used to investigate antifungal activity. Significant inhibitory activity of compounds 5c, 5d, 5e, 5f, 5m and 5n was evaluated against the Candida albicans (I), Candida albicans clinical isolate (II), Candida glabrata clinical isolate (I), and Candida glabrata (II) with minimum inhibitory concentrations (MIC80) values ranging from 2 to 16 µg/mL. Notably, compounds 5e and 5n showed the best inhibition against Candida albicans (II), Candida glabrata (I), and Candida glabrata (II) at the concentrations of 2 and 8 µg/mL, respectively. Molecular docking study revealed that the target compounds interacted with CYP51 mainly through hydrophobic and van der Waals interactions. The results indicated that these novel triazole derivatives could serve as promising leads for development of antifungal agents.
Keywords: antifungal activity; molecular docking; structure–activity relationship; synthesis; triazole.
Similar articles
-
Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.Bioorg Med Chem Lett. 2011 Aug 1;21(15):4471-5. doi: 10.1016/j.bmcl.2011.06.008. Epub 2011 Jun 15. Bioorg Med Chem Lett. 2011. PMID: 21737273
-
Design, synthesis, and structure-activity relationship studies of novel triazole agents with strong antifungal activity against Aspergillus fumigatus.Bioorg Med Chem Lett. 2020 Feb 15;30(4):126951. doi: 10.1016/j.bmcl.2020.126951. Epub 2020 Jan 7. Bioorg Med Chem Lett. 2020. PMID: 31926784
-
Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.Eur J Med Chem. 2014 Jul 23;82:490-7. doi: 10.1016/j.ejmech.2014.05.079. Epub 2014 Jun 2. Eur J Med Chem. 2014. PMID: 24934573
-
Current advancements and future perspectives of 1,2,3-triazoles to target lanosterol 14α-demethylase (CYP51), a cytochrome P450 enzyme: A computational approach.Int J Biol Macromol. 2025 Jun;315(Pt 1):144240. doi: 10.1016/j.ijbiomac.2025.144240. Epub 2025 May 17. Int J Biol Macromol. 2025. PMID: 40389011 Review.
-
CDATA[Recent Advances in the Development of 1,2,3-Triazole-containing Derivatives as Potential Antifungal Agents and Inhibitors of Lanoster ol 14α-Demethylase.Curr Top Med Chem. 2021;21(6):462-506. doi: 10.2174/1568026621999201214232018. Curr Top Med Chem. 2021. PMID: 33319673 Review.
Cited by
-
N-Phenacyldibromobenzimidazoles-Synthesis Optimization and Evaluation of Their Cytotoxic Activity.Molecules. 2022 Jul 7;27(14):4349. doi: 10.3390/molecules27144349. Molecules. 2022. PMID: 35889223 Free PMC article.
-
Triazole analogues as potential pharmacological agents: a brief review.Futur J Pharm Sci. 2021;7(1):106. doi: 10.1186/s43094-021-00241-3. Epub 2021 May 25. Futur J Pharm Sci. 2021. PMID: 34056014 Free PMC article. Review.